Estech employees help improve and save human lives by empowering heart surgeons with the optimal solutions for less invasive procedures.
Board of directors
Scott Halsted, Managing Director, Saints Capital
Mr. Halsted is currently a Managing Director for Saints. Prior to joining Saints, from 1987-2007 he was a managing member of Morgan Stanley Ventures where he was responsible for making growth equity investments in emerging health care companies. Mr. Halsted has served on seventeen Boards of Directors including both private and public companies. Prior to his investment career, Mr. Halsted worked in the medical technology field in the areas of product design and business development for Intermedics Orthopedics and Hexcel Medical. Mr. Halsted holds an AB degree from Dartmouth College as well as a BE degree in biomechanical engineering from the Thayer School of Engineering at Dartmouth College . He also holds an MM degree from Northwestern University.
Robert Shepler, Managing Director, Telegraph Hill Partners
Robert Shepler has served on the Company’s board since 2005 and is a Managing Director at Telegraph Hill Partners ("THP"), one of the Company’s principal investors. He has been a corporate transactions specialist and investor for over 30 years, with a focus on strategic M&A transactions. He and his partner, Matt Mackowski, formed THP's predecessor in 1991 to focus on investing in private healthcare companies. During his career, he has served on numerous company boards and completed over 150 M&A and financing transactions. In addition to ESTECH, his current directorships include AcroMetrix, Aurora Discovery, Inc., Applied Precision, Inc., LDR Spine, Inc. and VidaCare, Inc. Prior to joining with Mr. Mackowski, Mr. Shepler worked with Merrill Lynch & Co. as an officer in their San Francisco corporate finance office where he managed financings and acquisitions for Fortune 500 and selected high growth companies. Robert Shepler received a BA - Duke University and an MBA - New York University.
Aris Constantinides, Founder and Investment Director, NBGI Ventures
Aris is the founder and Investment Director of NBGI Ventures, responsible for its overall strategy and management, and leads its presence in the medical technology sector. Aris established NBGI Ventures in 2001, following five years in venture capital with Deutsche Bank’s venture capital team and CSFB’s Cabot Square Capital fund. He started his career at Bankers Trust as a derivatives specialist. Aris holds a B.Eng from Imperial College and a SM from MIT in Mechanical Engineering and an MBA from INSEAD.
Since 2002, Randy Lindholm has served as a director on numerous private and public company boards, and is currently a director at publicly traded Omnicell (NASDAQ:OMCL), as well as privately held Barrx Medical, Tibion Bionic Technologies, and Novasys Medical. Mr. Lindholm began his career in 1977 and spent 16 years with GE Medical Systems, serving in a variety of increasingly senior sales and marketing positions. From 1993 to 1997, Mr. Lindholm was vice president of field operations at Nellcor Puritan Bennett, a provider of solutions to diagnose, monitor and treat the respiratory-impaired patient. Nellcor Puritan Bennett was sold to Mallinckrodt in 1998 for $1.9B. Mr. Lindholm remained with Mallinckrodt for a one year transition period as Vice President of Respiratory Field Operations, where he led the field operations integration. In 1999 Mr. Lindholm was named chairman, president and CEO of VidaMed, Inc., a maker of minimally invasive medical device products that treated the urological condition of benign prostatic hyperplasia. VidaMed was acquired by Medtronic in April of 2002 for $326 million in cash.
John Pavlidis joined Estech in October 2008. Prior to that, he was President and CEO of R2 Technology Inc., the pioneer and leader in Computer Aided Detection of breast cancer and lung abnormalities. At R2 Pavlidis led the turnaround of the business, formed a new senior management team and implemented new processes and discipline for profitable growth. The company was acquired for $225 million in 2006 by Hologic, Inc., the leader in women’s health. From 2000 until 2004 Pavlidis was the president of the Siemens Ultrasound business worldwide. Pavlidis led the ultrasound business through significant restructuring and growth including the acquisition of USA market leader Acuson Corporation, expansion of R&D and manufacturing in Asia and market introduction of numerous products and upgrades. Siemens Ultrasound had reached revenues approaching $1 billion at the time of his departure. Pavlidis holds a master’s degree in Engineering Sciences from Dartmouth College in Hanover, New Hampshire and a bachelor’s degree in Biomedical Engineering from Rensselaer Polytechnic Institute in Troy, New York.